Specialty generics maker Akorn has nabbed another niche player. Fresh off the closing of its eye-care-oriented buyout of Hi-Tech Pharmacal, the Lake Forest, IL-based drug company has snapped up VersaPharm for $440 million.
written on 12.05.2014
Specialty generics maker Akorn has nabbed another niche player. Fresh off the closing of its eye-care-oriented buyout of Hi-Tech Pharmacal, the Lake Forest, IL-based drug company has snapped up VersaPharm for $440 million.
See our Cookie Privacy Policy Here